Myocarditis
Tóm tắt
Myocarditis and its sequela, dilated cardiomyopathy (DCM), cause substantial morbidity and mortality, especially in children and young adults. Physicians should include myocarditis in the differential diagnosis of all patients who have new symptoms of heart failure, arrhythmia, or chest pain syndromes of unclear cause, and should strongly consider performing endomyocardial biopsy (EMB) to establish the diagnosis. It may be necessary to perform multiple or serial biopsies to increase sensitivity. Patients with myocarditis and symptomatic heart failure, chest pain, or arrhythmias need hospitalization for evaluation and treatment. Patients with symptomatic left ventricular dysfunction should be treated with conventional heart failure therapy, including angiotensin-converting enzyme (ACE) inhibitors, digitalis, diuretics, and β-blockers. Patients with arrhythmias or syncope may require electrophysiologic evaluation. In addition to conventional therapy, physicians should consider a course of immunosuppressive therapy in selected patients. The clinical course, response to therapy, and left ventricular function need close monitoring. Patients with myocarditis and rapidly progressive heart failure or cardiogenic shock should be referred early to an advanced heart failure center for implantation of a ventricular assist device and consideration for cardiac transplantation.
Tài liệu tham khảo
Baboonian C, Davies MJ, Booth JC, et al.: Coxsackie B viruses and human heart disease. Curr Top Microbiol Immunol 1997, 223:31–52.
Why H, Meany T, Richardson P, et al.: Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy. Circulation 1994, 89:2582–2589.
Grogan M, Redfield MM, Bailer KR, et al.: Long-term outcome of patients with biopsy-proven myocarditis: comparison with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1995, 26:80–84.
Caforio ALP, Goldman JH, Haven AJ, et al.: Evidence for autoimmunity to myosin and other heart-specific autoantigens in patients with dilated cardiomyopathy and their relatives. Int J Cardiol 1996, 54:157–163.
Lauer B, Schannwell M, Kuhl U, et al.: Antimyosin antibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol 2000, 35:11–18.
McNamara DM, Starling RC, Dec W, et al., for the IMAC investigators: Prevalence of myocarditis in acute dilated cardiomyopathy. Congest Heart Fail 1999, 5:54.
Felker GM, Thompson RE, Hare JM, et al.: Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000, 342:1077–1084.
McCarthy RE III, Hruban RH, Kasper EK: Association between the incidence of histopathologic myocarditis and non-polio enterovirus isolates in the United States. Paper presented at the 71st Scientific Session of the American Heart Association, Dallas, TX, November 8–11, 1998.
Huber SA, Gauntt CJ, Sakkinen P: Enteroviruses and myocarditis: viral pathogenesis through replication, cytokine induction and immunopathogenicity. Adv Virus Res 1998, 51:35–80. Excellent review article detailing pathogenic mechanisms of myocarditis and DCM.
Wessely R, Klingel K, Santana LF, et al.: Transgenic expression of replication-restricted enteroviral genomes in heart muscle induces defective excitationcontraction coupling and dilated cardiomyopathy. J Clin Invest 1998, 102:1444–1453.
Bowles NE, Towbin JA: Molecular aspects of myocarditis. Curr Opin Cardiol 1998, 13:179–184.
Woodruff JF, Woodruff JJ: Involvement of T lymphocytes in the pathogenesis of Coxsackie virus B3 heart disease. J Immunol 1974, 113:1726–1734.
Aretz HT, Billingham ME, Edwards WB, et al.: Myocarditis. A histopathologic definition and classification. Cardiovasc Pathol 1987, 1:3–14.
McCarthy RE, Boehmer JP, Hruban RH, et al.: Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000, 342:690–695.
Winkel E, Costanzo MR: Chronic heart failure. Curr Treat Options Cardiovasc Med 1999, 1:231–241.
Maisch B, Herzum M, Hufnagel G, et al.: Immunosuppressive and immunomodulatory treatment for myocarditis. Curr Opin Cardiol 1996, 11:310–324.
Friman G, Illback NG: Acute infection: metabolic responses, effects on performance, interaction with exercise, and myocarditis. Int J Sports Med 1998, 19(suppl 3):S172-S182.
Parrillo JE, Cunnion RE, Epstein SE, et al.: A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 1989, 321:1061–1068. First major controlled trial of immunosuppressive therapy to treat inflammatory cardiomyopathy. A 3-month course of prednisone therapy improved LV function in an inflammatory or reactive form of DCM.
Latham RD, Mulrow JP, Virmani R, et al.: Incidence of myocarditis and efficacy of prednisone therapy. Am Heart J 1989, 117:876–881.
Mason JW, O’Connell JB, Herskowitz A, et al.: A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995, 333:269–275.
Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al.: Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy. Two-year follow-up results. Circulation 2001, 104:39–45.
Parrillo JE: Myocarditis: how should we treat in 1998? J Heart Lung Transplant 1998, 17:941–944.
Drucker NA, Colan SD, Lewis AB, et al.: Globulin treatment of acute myocarditis in the pediatric population. Circulation 1994, 89:252–257.
McNamara DM, Rosenblum WD, Janosko KM, et al.: Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation 1997, 95:2476–2478.
McNamara DM, Holubkov R, Starling RC, et al.: Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001, 103:2254–2259. First large controlled, randomized trial of immune globulin to treat myocarditis in adults. It showed no benefit.
Stille-Siegener M, Heim A, Figulla HR: Subclassification of dilated cardiomyopathy and interferon treatment. Eur Heart J 1995, 16(suppl O):147–149.
Miric M, Miskovic A, Brkic S: Long-term follow-up of patients with myocarditis and idiopathic dilated cardiomyopathy after immunomodulatory therapy. FEMS Immunol Med Microbiol 1994, 10:65–74.
Zhang H, Soteriou B, Knowlson S, et al.: Characterisation of genomic RNA of coxsackie B3 in murine myocarditis: reliability of direct sequencing of reverse transcription-nested polymerase chain reaction products. J Virol Methods 1997, 69:7–17.
Ni J, Bowles NE, Kim YH, et al.: Viral infection of the myocardium in endocardial fibroelastosis. Molecular evidence for the role of mumps virus as an etiologic agent. Circulation 1997, 95:133–139.